EGFR and prostate carcinoma: From the 303 biopsies with adequate tumour content (tumour cellularity ≥ 10%), 159 (52.5%) were included in cohort 1 (Global Match-R), 12 (4%) in cohort 2 (NSCLC EGFR + /ALK+), 57 (18.8%) in cohort 3 (Immunotherapy) and 75 (24.8%) in cohort 4 (Prostate cancer) (Supplementary Table 1).